Key performance indicators of the Group and its businesses

The three key performance indicators of net sales, EBITDA pre and operating cash flow (OCF) are the most important financial indicators for assessing our operational performance. Accordingly, we refer to these KPIs in the Report on Economic Position, the Report on Risks and Opportunities and the Report on Expected Developments. As the most important indicators of financial business performance, the KPIs are key elements of our performance management system.

Net sales

Net sales are defined as the revenues from the sale of goods, services rendered to external customers and commission income and profit sharing from collaborations, net of value-added tax and after-sales deductions such as rebates or discounts. Net sales are the main indicator of our business growth and are therefore an important parameter of both external and internal performance measurement. In addition, organic sales growth compared with the annual target is used for internal performance management. Organic sales growth shows the percentage change in net sales versus a comparative period, adjusted for foreign exchange and portfolio effects. Foreign exchange effects may arise as a result of foreign exchange fluctuations between the functional non-euro currency of a consolidated company and the reporting currency (euro). By contrast, portfolio effects reflect sales changes due to acquisitions and divestments of consolidated companies or businesses.

Group

Net sales

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Change

€ million

 

2025

 

2024

 

€ million

 

%

Net sales

 

21,102

 

21,156

 

-54

 

-0.3%

EBITDA pre

EBITDA pre is the main performance indicator measuring ongoing operational profitability and is used internally and externally. To permit a better understanding of the underlying operational performance, the operating result is adjusted to exclude depreciation and amortization, impairment losses and reversals of impairment losses, as well as adjustments. These adjustments are restricted to the following categories: integration expenses, IT expenses for certain projects, restructuring expenses, gains/losses on the divestment of businesses, acquisition expenses, and other adjustments. The classification of specific income and expenses as adjustments follows clear rules and is subject to strict governance at the Group level. Within the scope of internal performance management, EBITDA pre allows for efficiency improvements to be implemented in processes without the performance of the operating business being affected by exceptional items or restructuring expenses. In addition, organic EBITDA pre growth compared with the annual target is used for internal performance management. The following table shows the composition of EBITDA pre in fiscal 2025 compared with the previous year. The IFRS Accounting Standards figures have been modified to reflect the elimination of adjustments included in the respective functional costs.

Group

Reconciliation EBITDA pre1

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2025

 

2024

 

Change

€ million

 

IFRS

 

Elimination of adjust­ments

 

pre1

 

IFRS

 

Elimination of adjust­ments

 

pre1

 

pre1

Net sales

 

21,102

 

 

21,102

 

21,156

 

 

21,156

 

-0.3%

Cost of sales

 

-8,756

 

113

 

-8,643

 

-8,671

 

41

 

-8,630

 

0.1%

Gross profit

 

12,346

 

113

 

12,459

 

12,485

 

41

 

12,526

 

-0.5%

Marketing and selling expenses

 

-4,562

 

71

 

-4,491

 

-4,536

 

30

 

-4,506

 

-0.3%

Administration expenses

 

-1,437

 

132

 

-1,305

 

-1,370

 

154

 

-1,216

 

7.4%

Research and development costs

 

-2,415

 

33

 

-2,381

 

-2,279

 

11

 

-2,269

 

5.0%

Impairment losses and reversal of impairment losses on financial assets (net)

 

15

 

 

15

 

-8

 

2

 

-7

 

>100.0%

Other operating income and expenses

 

-347

 

230

 

-117

 

-646

 

333

 

-313

 

-62.7%

Operating result (EBIT)1

 

3,601

 

 

 

 

 

3,645

 

 

 

 

 

 

Depreciation/amortization/impairment losses/reversals of impairment losses

 

2,298

 

-369

 

1,929

 

2,134

 

-277

 

1,856

 

3.9%

EBITDA2

 

5,899

 

 

 

 

 

5,779

 

 

 

 

 

 

Restructuring expenses

 

174

 

-174

 

 

144

 

-144

 

 

 

Integration expenses/IT expenses

 

193

 

-193

 

 

103

 

-103

 

 

 

Gains (-)/losses (+) on the divestment of businesses

 

-88

 

88

 

 

-46

 

46

 

 

 

Acquisition-related adjustments

 

44

 

-44

 

 

26

 

-26

 

 

 

Other adjustments

 

-113

 

113

 

 

68

 

-68

 

 

 

EBITDA pre1

 

6,109

 

 

6,109

 

6,072

 

 

6,072

 

0.6%

thereof: organic growth1

 

 

 

 

 

 

 

 

 

 

 

 

 

5.6%

thereof: exchange rate effects

 

 

 

 

 

 

 

 

 

 

 

 

 

-5.0%

thereof: acquisitions/divestments

 

 

 

 

 

 

 

 

 

 

 

 

 

1

Not defined by IFRS Accounting Standards.

2

Not defined by IFRS Accounting Standards; EBITDA corresponds to operating result (EBIT) adjusted by depreciation, amortization, impairment losses, and reversals of impairment losses.

Operating cash flow (OCF)/free cash flow as of 2026

Operating cash flow results from the company’s current business activities and describes the cash generated from operating activities. It is influenced mainly by EBITDA pre, income tax, financial income and expenses, and changes in net working capital.

As of fiscal 2026, free cash flow will replace operating cash flow as the key performance indicator. The more comprehensive free cash flow indicator aims to achieve holistic, sustainable cash governance and further strengthens capital discipline. Free cash flow is defined as operating cash flow less payments for investments in intangible assets and property, plant and equipment and plus proceeds from the disposal of intangible assets and property, plant and equipment and less lease payments. In order to provide the best possible understanding of the underlying actual cash performance, certain payments and proceeds in connection with the purchase and divestment of intangible assets and property, plant and equipment, especially those relating to collaboration and licensing agreements, are not included in free cash flow. This is because these are irregular payments that can significantly distort the performance indicator due to their potential magnitude and timing.

Group

Free cash flow

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Change

€ million

 

2025

 

2024

 

€ million

 

%

EBITDA pre1

 

6,109

 

6,072

 

37

 

0.6%

Adjustments1

 

-210

 

-293

 

83

 

-28.4%

Financial income and expenses2

 

-293

 

-108

 

-184

 

>100.0%

Income tax2

 

-693

 

-751

 

58

 

-7.7%

Changes in working capital1

 

-349

 

-63

 

-286

 

>100.0%

thereof: Changes in inventories3

 

-257

 

36

 

-293

 

>100.0%

thereof: Changes in trade accounts receivable3

 

-166

 

79

 

-245

 

>100.0%

thereof: Changes in trade accounts payable/refund liabilities3

 

73

 

-178

 

251

 

>100.0%

Changes in provisions3

 

124

 

62

 

61

 

98.4%

Changes in other assets and liabilities3

 

-588

 

-309

 

-279

 

90.4%

Neutralization of gains/losses on disposal of fixed assets and other disposals3

 

-164

 

-2

 

-162

 

>100.0%

Other non-cash income and expenses3

 

-4

 

-22

 

18

 

-84.0%

Operating cash flow

 

3,932

 

4,586

 

-654

 

-14.3%

Adjusted payments for investments in intangible and tangible assets4

 

-1,758

 

-1,854

 

96

 

-5.2%

Adjusted proceeds from the disposal of intangible and tangible assets4

 

30

 

31

 

 

-0.8%

Payments for leasing

 

-153

 

-139

 

-14

 

10.1%

Free cash flow

 

2,052

 

2,624

 

-573

 

-21.8%

1

Not defined by IFRS Accounting Standards. Adjustments according to the definition above.

2

According to the Consolidated Income Statement.

3

According to the Consolidated Cash Flow Statement.

4

Please refer to the following table for the components of the adjustments.

Adjusted investment payments

 

 

Payments for investments in intangible assets and tangible assets

 

Proceeds from the disposal of intangible assets and tangible assets

€ million

 

2025

 

2024

 

2025

 

2024

Investment payments1

 

-1,958

 

-2,183

 

196

 

44

Adjustments proceeds (-)/payments (+)

 

 

 

 

 

 

 

 

Collaboration and licensing agreements

 

200

 

330

 

-14

 

-14

Sale of a U.S. Food and Drug Administration Priority Review Voucher

 

 

 

 

 

-151

 

Adjusted investment payments

 

-1,758

 

-1,854

 

30

 

31

1

As reported in the Consolidated Cash Flow Statement.

Share this page: